1. JDRF Research and Partnerships to Improve the Lives of People with Type 1 Diabetes and Keep our Promise of a Cure Boston, April 6, 2010 Karin Hehenberger, MD, PhD Senior Vice President, Strategic Alliances

6. Preventing through Earlier Diagnostics Interventions based on earlier diagnostics % Beta Cells Time ( Years ) At-Risk Sub-Clinical Recent Onset Established (without Complications) Established (with Complications) Current diagnosis based on glucose Early diagnosis based on auto-antibodies

8. Preventing and Treating Complications Discover, develop, deliver therapies to prevent, arrest, and reverse diabetic complications

13. Curing by Implanting Encapsulated Beta cells Immune Cells Complement 0 2 Nutrients GLUCOSE INSULIN C-Peptide Human Islet PEG 25-50 

16. Exploratory research Target ID/Validation Lead identification Lead optimization Clinical development Generate new beta cells Beta Cell Survival Beta Cell Growth Reprogram JDRF has Formed Partnerships with NVS, JNJ and PFE in Regeneration and Pursuing Further Partners…..

18. TolerX Anti-CD3 Immunotherapy in Recent Onset Diabetes Increased Preservation of Functional Beta Cell Mass for 4 Years Diabetologia (2010) 53:614–623

20. Appendix

21. Beta Cell Therapies Current Industry Partners

22. Immune Therapies Current Industry Partners (Continued)

23. Current Industry Partners (Continued) Glucose Control Complications Therapies

24. JDRF Venture Capital Industry People with Type 1 Diabetes Providers Academia Funders FDA Payers JDRF JDRF’s Partners